Summary by Futu AI
On February 29, 2024, Clene Inc. announced the presentation of positive clinical results from the VISIONARY-MS trial long-term extension (LTE) for its CNM-Au8 30mg treatment in patients with multiple sclerosis (MS). The results were presented at the annual Americas Committee for Treatment and Research in MS (ACTRIMS) Forum 2024. The study showed significant and clinically meaningful improvements in vision and cognition in MS patients over a period of 35 months. The treatment was well-tolerated with high compliance and no serious adverse events attributed to CNM-Au8. Clene Inc., a clinical-stage biopharmaceutical company, focuses on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases. The company's investigational therapy, CNM-Au8, targets mitochondrial function and the NAD pathway while reducing oxidative stress. The VISIONARY-MS trial was a Phase 2 multi-center, randomized, double-blind, placebo-controlled trial that evaluated the efficacy and safety of CNM-Au8 in stable relapsing MS patients with chronic optic neuropathy.